



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

UTN801 : Endometrium normal adjacent tissue (NAT) and endometrium cancer tissue array, including pathology grade, TNM and clinical stage, 79 cases/80 cores (1.5 mm).

Microarray Panel	Endometrium tissue and endometrium carcinoma tissue microarray, containing 70 case endometrium tissue (25 secretory endometrium tissue, 44 proliferative endometrium tissue, 1 endometrium tissue), 9 endometrioid adenocarcinoma, 1 adenosquamous carcinoma, single core per block	
Cores	80	
Cases	79	
Row number	8	
Column number	10	
Core Diameter (mm)	1.5	
Thickness (µm)	5	
QA/QC	H&E, IHC Vimentin	
Tissue Array Type	FFPE	
Species	Human	
Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.	
Notes	<p>1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for deparaffinization. Baked slides were sent out baked for 2 hours.</p> <p>In the following specsheet, “*” means invalid core; “-” means no applicable or negative in IHC markers.</p>	

	1	2	3	4	5	6	7	8	9	10
A	Ute									
B	Ute									
C	Ute									
D	Ute									
E	Ute									
F	Ute									
G	Ute									
H	Ute Adr									

Legend: Ute - Uterus

● - Malignant tumor,
 ● - Malignant tumor (stage I),
 ● - Malignant tumor (stage IB),
 ● - Malignant tumor (stage IC),
 ● - Malignant tumor (stage II),
 ● - Malignant tumor (stage IIA),
 ● - NAT

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	54	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
A2	2	46	F	Uterus	Intermediate stage proliferative endometri...	-	-	-	NAT	
A3	3	46	F	Uterus	Early stage secretory endometrium tissue	-	-	-	NAT	
A4	4	52	F	Uterus	Early-intermediate stage secretory endometri...	-	-	-	NAT	
A5	5	45	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	

A6	6	58	F	Uterus	Early-intermediate stage proliferative endometrium tissue	-	-	-	NAT	
A7	7	47	F	Uterus	Advanced stage proliferative endometrium tissue	-	-	-	NAT	
A8	8	44	F	Uterus	Intermediate-advanced stage secretory endometrium tissue	-	-	-	NAT	
A9	9	57	F	Uterus	Intermediate stage proliferative endometrium issue	-	-	-	NAT	
A10	10	21	F	Uterus	Advanced stage secretory endometrium tissue	-	-	-	NAT	
B1	11	27	F	Uterus	Advanced stage secretory endometrium tissue	-	-	-	NAT	
B2	12	60	F	Uterus	Proliferative endometrium tissue	-	-	-	NAT	
B3	13	52	F	Uterus	Intermediate stage proliferative endometrium issue	-	*	-	NAT	
B4	14	59	F	Uterus	Endometrium tissue (sparse)	-	-	-	NAT	
B5	15	49	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
B6	16	53	F	Uterus	Proliferative endometrium tissue	-	*	-	NAT	
B7	17	56	F	Uterus	Advanced stage secretory endometrium tissue	-	-	-	NAT	
B8	18	50	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
B9	19	60	F	Uterus	Intermediate stage proliferative endometrium issue	-	-	-	NAT	
B10	20	45	F	Uterus	Advanced stage proliferative endometrium tissue	-	-	-	NAT	
C1	21	50	F	Uterus	Intermediate stage proliferative endometrium issue	-	-	-	NAT	
C2	22	50	F	Uterus	Early stage secretory endometrium tissue	-	-	-	NAT	
C3	23	62	F	Uterus	Intermediate stage secretory endometrium tissue	-	-	-	NAT	
C4	24	58	F	Uterus	Intermediate stage secretory endometrium tissue	-	-	-	NAT	
C5	25	41	F	Uterus	Intermediate-advanced stage secretory endometrium tissue	-	-	-	NAT	
C6	26	34	F	Uterus	Intermediate-advanced stage proliferative endometrium tissue	-	-	-	NAT	
C7	27	41	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
C8	28	44	F	Uterus	Advanced stage secretory endometrium tissue	-	-	-	NAT	
C9	29	44	F	Uterus	Intermediate-advanced stage proliferative endometrium tissue	-	-	-	NAT	
C10	30	42	F	Uterus	Intermediate-advanced stage proliferative endometrium tissue	-	-	-	NAT	
D1	31	31	F	Uterus	Intermediate stage proliferative endometrium issue	-	-	-	NAT	
D2	32	64	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
D3	33	35	F	Uterus	Advanced stage secretory endometrium tissue	-	-	-	NAT	
D4	34	25	F	Uterus	Intermediate stage proliferative endometrium issue	-	-	-	NAT	
D5	35	40	F	Uterus	Intermediate stage proliferative endometrium issue	-	-	-	NAT	
D6	36	58	F	Uterus	Intermediate-advanced stage secretory endometrium tissue	-	-	-	NAT	
D7	37	52	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
D8	38	29	F	Uterus	Advanced stage proliferative endometrium tissue	-	-	-	NAT	
D9	39	50	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
D10	40	32	F	Uterus	Intermediate stage proliferative endometrium issue	-	-	-	NAT	

E1	41	12	F	Uterus	Advanced stage proliferative endometrium tissue	-	-	-	NAT
E2	42	57	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT
E3	43	58	F	Uterus	Early stage proliferative endometrium tissue of No.75	-	-	-	NAT
E4	44	42	F	Uterus	Intermediate stage proliferative endometrium issue	-	-	-	NAT
E5	45	28	F	Uterus	Intermediate-advanced stage secretory endometrium tissue	-	-	-	NAT
E6	46	48	F	Uterus	Intermediate stage proliferative endometrium issue	-	*	-	NAT
E7	47	42	F	Uterus	Early stage proliferative endometrium tissue	-	*	-	NAT
E8	48	48	F	Uterus	Intermediate-advanced stage proliferative endometrium tissue	-	-	-	NAT
E9	49	31	F	Uterus	Intermediate stage secretory endometrium tissue	-	-	-	NAT
E10	50	51	F	Uterus	Intermediate stage secretory endometrium tissue	-	-	-	NAT
F1	51	27	F	Uterus	Early stage secretory endometrium tissue	-	-	-	NAT
F2	52	35	F	Uterus	Advanced stage secretory endometrium tissue	-	-	-	NAT
F3	53	36	F	Uterus	Early stage secretory endometrium tissue	-	-	-	NAT
F4	54	30	F	Uterus	Intermediate stage secretory endometrium tissue	-	-	-	NAT
F5	55	52	F	Uterus	Intermediate-advanced stage proliferative endometrium tissue	-	-	-	NAT
F6	56	47	F	Uterus	Advanced stage proliferative endometrium tissue	-	-	-	NAT
F7	57	51	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT
F8	58	42	F	Uterus	Early stage secretory endometrium tissue	-	-	-	NAT
F9	59	58	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT
F10	60	36	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT
G1	61	41	F	Uterus	Intermediate stage secretory endometrium tissue	-	-	-	NAT
G2	62	43	F	Uterus	Advanced stage proliferative endometrium tissue	-	-	-	NAT
G3	63	38	F	Uterus	Intermediate stage secretory endometrium tissue	-	-	-	NAT
G4	64	42	F	Uterus	Intermediate stage secretory endometrium tissue (sparse)	-	-	-	NAT
G5	65	52	F	Uterus	Intermediate stage proliferative endometrium issue	-	-	-	NAT
G6	66	54	F	Uterus	Advanced stage proliferative endometrium tissue	-	-	-	NAT
G7	67	56	F	Uterus	Intermediate stage proliferative endometrium issue	-	-	-	NAT
G8	68	57	F	Uterus	Intermediate stage secretory endometrium tissue	-	-	-	NAT
G9	69	50	F	Uterus	Intermediate stage proliferative endometrium issue	-	-	-	NAT
G10	70	45	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT
H1	71	52	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	IC	Malignant
H2	72	62	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant
H3	73	48	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant
H4	74	34	F	Uterus	Endometrioid adenocarcinoma	T2aN0M0	1	IIA	Malignant
H5	75	58	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	IC	Malignant
H6	76	55	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1--2	IC	Malignant
H7	77	56	F	Uterus	Endometrioid adenocarcinoma	T2aN0M0	*	IIA	Malignant
H8	78	74	F	Uterus	Endometrioid adenocarcinoma	T2N0M0	2--3	II	Malignant
H9	79	54	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2--3	IC	Malignant

H10	80	66	F	Uterus	Adenosquamous carcinoma	T1N0M0	-	I	Malignant
-	0	42	M	Adrenal gland	Pheochromocytoma (tissue marker)		-		Malignant

TNM grading:

T - Primary tumor

Tx - Primary tumor cannot be assessed

T0 - No evidence of primary tumor

Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria

T1 - Tumor invades submucosa

T2 - Tumor invades muscularis propria

T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.

T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes

Nx - Regional lymph nodes cannot be assessed

N0 - No regional lymph node metastasis

N1 - Metastasis in 1 to 3 regional lymph nodes

N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis

Mx - Distant metastasis cannot be assessed

M0 - No distant metastasis

M1 - Distant metastasis

AMSBIO | www.amsbio.com | info@amsbio.com



UK & Rest of the World

184 Park Drive, Milton Park
Abingdon OX14 4SE, U.K.
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482



North America

1035 Cambridge Street,
Cambridge, MA 02141.
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218



Germany

Bockenheimer Landstr. 17/19
60325 Frankfurt/Main
T: +49 (0) 69 779099
F: +49 (0) 69 13376880



Switzerland

Via Lisano 3
(CP.683)
6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85